How to Find the Best Small-Cap Stocks to Buy
Wall Street's best small-cap stocks to buy include biotech, real estate and industrials names.


The second half of 2024 could be much more favorable for stockpickers looking for the best small-cap stocks to buy.
That might sound counterintuitive after the way small caps performed through the first half of the year. After all, small caps as an asset class have been a dud. They went nowhere as mega-cap stocks pushed the broader market to record highs seemingly every other day.
To recap: the S&P 500 gained almost 15% on a price basis through the first half of the year, while the tech-heavy Nasdaq Composite rose nearly 18%. The Dow Jones Industrial Average rose just 4%, hurt by its price-weighted construction.

Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
But while select Magnificent 7 stocks such as Nvidia (NVDA), Apple (AAPL) and Microsoft (MSFT) drove the majority of the market's gains, small caps – which tend to be more sensitive to the economic cycle and interest rates – traded sideways. Indeed, the small-cap benchmark Russell 2000 Index – struggling to stay positive for months – was slightly negative as we closed out the first half.
"Since the bull market began, a glaring feature has been the dominance of large caps (proxied by the S&P 500) and the lack of meaningful upside for small caps (proxied by the Russell 2000)," writes Liz Ann Sonders, chief investment strategist at Charles Schwab. "We think the fact that higher rates are putting more pressure on small companies' profitability is driving the performance gap."
Small-cap stocks are cheap
If there is a sliver of a silver lining to the Russell 2000's underperformance, it's that small caps are now trading at bargain basement prices.
"Small caps stocks are historically cheap versus just about every other equity asset class," writes Grant Engelbart, investment strategist at Carson Group. "While this large valuation discount does not provide any sense of timing, it is still a tailwind for the asset class."
The strategist adds that small company earnings growth appears to have "troughed over the past year, setting up future year expectations in a big way." According to current estimates, analysts see small-cap earnings growth surpassing that of S&P 500 companies in 2025 and 2026.
And with the Federal Reserve expected to enact at least one quarter-point cut to the federal funds rate before year-end, small caps should have at least one catalyst on the horizon.
Best small-caps stocks to buy
In order to find the best small-cap stocks to buy now, we started by screening the Russell 2000 for Wall Street analysts' top-rated names.
Here's how the process works: S&P Global Market Intelligence surveys analysts' stock ratings and scores them on a five-point scale, where 1.0 equals Strong Buy and 5.0 means Strong Sell. Any score of 2.5 or lower means that analysts, on average, rate the stock a Buy. The closer the score gets to 1.0, the stronger the Buy call.
In other words, lower scores are better than higher scores.
We further limited ourselves to stocks with at least 10 Strong Buy recommendations (in order to ensure adequate analyst coverage and sample size). Lastly, we dug into research, fundamental factors, valuation, analysts' estimates and other data on the top names.
Our screen of the Street's best small-cap stocks served up a list dominated by the healthcare sector, mostly pharmaceutical and biotechnology companies. That's to be expected, and investors should always do their own due diligence when considering, say, a clinical-stage biotech firm, which is essentially a speculative investment.
In other cases, some of these names – a couple of industrials stocks and a REIT – might just surprise you.
And with that, have a look at the table below to see Wall Street's best small-cap stocks to buy now.
Company (Ticker) | Sector | Analysts' Consensus Recommendation Score | Analysts' Consensus Recommendation |
---|---|---|---|
BrightSpring Health Services (BTSG) | Healthcare | 1.17 | Strong Buy |
Parsons (PSN) | Industrials | 1,18 | Strong Buy |
Immunovant (IMVT) | Biotechnology | 1.27 | Strong Buy |
Enovix (ENVX) | Industrials | 1.31 | Strong Buy |
Insmed (INSM) | Biotechnology | 1.31 | Strong Buy |
Rocket Pharmaceuticals (RCKT) | Biotechnology | 1.33 | Strong Buy |
Arcellx (ACLX) | Biotechnology | 1.35 | Strong Buy |
Kura Oncology (KURA) | Biotechnology | 1.36 | Strong Buy |
Essential Properties Realty Trust (EPRT) | Real Estate | 1.36 | Strong Buy |
Axsome Therapeutics (AXSM) | Pharmaceuticals | 1.38 | Strong Buy |
Get Kiplinger Today newsletter — free
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.

Dan Burrows is Kiplinger's senior investing writer, having joined the publication full time in 2016.
A long-time financial journalist, Dan is a veteran of MarketWatch, CBS MoneyWatch, SmartMoney, InvestorPlace, DailyFinance and other tier 1 national publications. He has written for The Wall Street Journal, Bloomberg and Consumer Reports and his stories have appeared in the New York Daily News, the San Jose Mercury News and Investor's Business Daily, among many other outlets. As a senior writer at AOL's DailyFinance, Dan reported market news from the floor of the New York Stock Exchange.
Once upon a time – before his days as a financial reporter and assistant financial editor at legendary fashion trade paper Women's Wear Daily – Dan worked for Spy magazine, scribbled away at Time Inc. and contributed to Maxim magazine back when lad mags were a thing. He's also written for Esquire magazine's Dubious Achievements Awards.
In his current role at Kiplinger, Dan writes about markets and macroeconomics.
Dan holds a bachelor's degree from Oberlin College and a master's degree from Columbia University.
Disclosure: Dan does not trade individual stocks or securities. He is eternally long the U.S equity market, primarily through tax-advantaged accounts.
-
AI Goes To School
The Kiplinger Letter Artificial intelligence is rapidly heading to K-12 classrooms nationwide. Expect tech companies to cash in on the fast-emerging trend.
-
Where to Invest in an Uncertain Market
In an uncertain market, you can still pocket juicy payouts ranging from 4% to 14%, depending on risk.
-
Where to Invest in an Uncertain Market
In an uncertain market, you can still pocket juicy payouts ranging from 4% to 14%, depending on risk.
-
My First $1 Million: Events Industry CEO, 65, Northern New Jersey
Ever wonder how someone who's made a million dollars or more did it? Kiplinger's My First $1 Million series uncovers the answers.
-
Social Security Pop Quiz: Are You Among the 89% of Americans Who'd Fail?
Shockingly few people have any clue what their Social Security benefits could be. This financial adviser notes it's essential to understand that info and when it might be best to access your benefits.
-
Stock Market Today: Investors Look on the Bright Side
A generally good week closes on another positive note, as investors, traders and speculators look for fresh catalysts.
-
My Three-Day Rule for Investing: And If it Applies Now
Stock Market I've seen a lot in my career. Here's what I see now in the stock market.
-
Such Attractive Yields in High-Grade Munis Are Rare and May Not Last Long
According to this munis expert, the last time munis were this cheap was a brief period in 2023. If you kicked yourself for missing out then, you have a second chance now.
-
Financial Analyst Sees a Bright Present for Municipal Bond Investors
High-tax-bracket investors have an excellent opportunity to secure low-volatility, high-quality returns at yield levels rarely seen in over a decade.
-
I'm an Insurance Pro: How Not to Get Dumped by Your Insurance Agent
Your insurance agent or broker might show you the door if you do any of these five things. Being a good customer is about more than paying your bill on time.